Evaluation of laboratory parameters in inflammatory myositis

Öz

Aim: Polymyositis (PM) and dermatomyositis (DM) are the two most common forms of idiopathic inflammatory myositis (IIM) and they are generally rare diseases. We evaluate the relationship of C-reactive protein (CRP)/albumin ratio (CAR), neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio and other inflammatory markers with IIM. Material and Methods: 30 patients and 30 healthy volunteers aged >18 years were included. Demographic data such as age, gender were recorded. CRP, erythrocyte sedimentation rate (ESR), albumin values, leukocyte, neutrophil, lymphocyte, platelet counts were determined. Results: The median (IQR) age of the patients and healthy volunteers were 46 (38-60) years and 45 (42-52) years, respectively. 50% of the patients had a diagnosis of DM and 50% of them had a diagnosis of PM, and the median (IQR) duration of disease was 4 (0.5-13) years. The median value of CAR was 3.6 (1.0-5.1) in the patient group and 0.3 (0.1-0.6) in the control group; the NLR was 3.4 (2.3-4.4) in the patient group, 1.8 (1.6-2.1) in the control group; PLR was 223 (157-249) in the patient group, 107 (100-125) in the control group and CAR, NLR, and PLR values between the groups were significantly different (p<0.001, p=0.002 and p=0.040, respectively). Conclusion: CAR can be considered as a helpful assessment tool to show inflammation in patients with IIM.

Anahtar Kelimeler

• Idiopathic inflammatory myopathies
• C-Reactive Protein / analysis*
• Inflammation / immunology
• Lymphocytes / metabolism*
• Neutrophils / immunology

İnflamatuar miyozitte laboratuvar parametrelerinin değerlendirilmesi

Öz

Amaç: Polimiyozit (PM) ve dermatomiyozit (DM), idiyopatik inflamatuar miyozitin (İİM) en sık görülen iki formudur ve genellikle nadir görülen hastalıklardır. C-reaktif protein (CRP)/albümin oranı (CAR), nötrofil/lenfosit oranı (NLR), trombosit/lenfosit oranı ve diğer inflamatuar belirteçlerin İİM ile ilişkisini değerlendirmeyi amaçladık. Gereç ve Yöntemler: 18 yaş üstü, 30 hasta ve 30 sağlıklı gönüllü dahil edildi. Yaş, cinsiyet gibi demografik veriler kaydedildi. CRP, eritrosit sedimantasyon hızı (ESR), albümin değerleri, lökosit, nötrofil, lenfosit, trombosit sayıları belirlendi. Bulgular: Hastaların ve sağlıklı gönüllülerin medyan (IQR) yaşı sırasıyla 46 (38-60) yıl ve 45 (42-52) yıl idi. Hastaların %50'sine DM, %50'sine PM tanısı konuldu ve ortanca (IQR) hastalık süresi 4 (0,5-13) yıldı. CAR medyan değeri hasta grubunda 3,6 (1,0-5,1) ve kontrol grubunda 0,3 (0,1-0,6); NLR hasta grubunda 3,4 (2,3-4,4), kontrol grubunda 1,8 (1,6-2,1) idi; Hasta grubunda PLR 223 (157-249), kontrol grubunda 107 (100-125) ve gruplar arasında CAR, NLR ve PLR değerleri anlamlı olarak farklıydı (sırasıyla, p<0,001, p=0,002 ve p=0,040). Sonuç: CRP/albumin oranı, IIM'li hastalarda inflamasyonu göstermek için yararlı bir değerlendirme aracı olarak düşünülebilir.

Anahtar Kelimeler

• İdiyopatik inflamatuar miyopatiler
• C-Reaktif Protein
• İnflamasyon
• Lenfositler
• Nötrofiller

Kaynakça

1. 1. Furst D.E., et al., Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve, 2012; 45: 676-83.
2. 2. Ha Y.J., et al., Baseline peripheral blood neutrophil-to-lymphocyte ratio could predict survival in patients with adult polymyositis and dermatomyositis: A retrospective observational study. PLoS One, 2018; 1: 0190411.
3. 3. Marie I., et al., Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol, 2001; 28: 2230-7.
4. 4. Airio A, H. Kautiainen, and M. Hakala, Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol, 2006; 25: 234-9.
5. 5. Benbassat, J., et al. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum, 1985; 28: 249-55.
6. 6. BOHAN, A., et al., A COMPUTER-ASSISTED ANALYSIS OF 153 PATIENTS WITH POLYMYOSITIS AND DERMATOMYOSITIS. Medicine, 1977; 56: 255-86.
7. 7. Carpenter, J.R., et al., Survival in polymyositis: corticosteroids and risk factors. J Rheumatol, 1977; 4: 207-14.
8. 8. DeVere, R. and W.G. Bradley. Polymyositis: its presentation, morbidity and mortality. Brain, 1975; 98: 637-66.

9. 9. Dankó, K., et al. Long-Term Survival of Patients With Idiopathic Inflammatory Myopathies According to Clinical Features: A Longitudinal Study of 162 Cases. Medicine, 2004; 83: 35-42.
10. 10. Henriksson, K.G. and P. Sandstedt .Polymyositis--treatment and prognosis. A study of 107 patients. Acta Neurol Scand, 1982; 65: 280-300.
11. 11. Hochberg, M.C., D. Lopez-Acuna, and A.M. Gittelsohn, Mortality from polymyositis and dermatomyositis in the United States, 1968-1978. Arthritis Rheum, 1983; 26: 1465-71.
12. 12. Lynn, S.J., et al., Adult-onset inflammatory myopathy: North Canterbury experience 1989–2001. Internal Medicine Journal, 2005; 35: 170-3.
13. 13. Mustafa, K.N. and S.S. Dahbour, Clinical characteristics and outcomes of patients with idiopathic inflammatory myopathies from Jordan 1996-2009. Clin Rheumatol, 2010; 29: 1381-5.
14. 14. Schiopu, E., et al., Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Research & Therapy, 2012; 14: 22.
15. 15. Torres, C., et al., Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity, 2006; 39: 205-15.
16. 16. Yamasaki, Y., et al., Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol, 2011; 38: 1636-43.
17. 17. Yu, K.H., et al., Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol, 2011; 30: 1595-601.
18. 18. Uthman, I., D. Vázquez-Abad, and J.L. Senécal, Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum, 1996; 26: 447-58.
19. 19. Maugars, Y.M., et al., Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol, 1996; 14: 263-74.
20. 20. Marie, I., Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep, 2012; 14: 275-85.
21. 21. Dalakas, M.C., Inflammatory muscle diseases. N Engl J Med, 2015; 372: 1734-47.
22. 22. Salvador, F.B. and D.A. Isenberg, Outcome predictors in patients with idiopathic inflammatory myopathies. Clin Exp Rheumatol, 2012; 30: 980.
23. 23. Lu, X., Q. Peng, and G. Wang, Discovery of new biomarkers of idiopathic inflammatory myopathy. Clin Chim Acta, 2015; 444: 117-25.
24. 24. Templeton, A.J., et al., Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst, 2014; 106: 124.
25. 25. Xu, X.L., et al., A Novel Inflammation-Based Prognostic Score, the C-Reactive Protein/Albumin Ratio Predicts the Prognosis of Patients with Operable Esophageal Squamous Cell Carcinoma. PLoS One, 2015; 10: 0138657.
26. 26. Ishizuka, M., et al., Clinical Significance of the C-Reactive Protein to Albumin Ratio for Survival After Surgery for Colorectal Cancer. Ann Surg Oncol, 2016; 23: 900-7.
27. 27. Rifaioglu, E.N., et al., Neutrophil to lymphocyte ratio in Behçet's disease as a marker of disease activity. Acta Dermatovenerol Alp Pannonica Adriat, 2014; 23: 65-7.
28. 28. Uslu, A.U., et al., Two new inflammatory markers associated with Disease Activity Score-28 in patients with rheumatoid arthritis: neutrophil-lymphocyte ratio and platelet-lymphocyte ratio. Int J Rheum Dis, 2015; 18: 731-5.
29. 29. Qin, B., et al., Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol, 2016; 26: 372-6.
30. 30. Peng, Y.F., et al., Platelet to Lymphocyte Ratio in Polymyositis as a Marker of Disease Activity. Clin Lab, 2016; 62; 915-9.
31. 31. Gao, M.Z., et al., Red blood cell distribution width and neutrophil to lymphocyte ratio are correlated with disease activity of dermatomyositis and polymyositis. J Clin Lab Anal, 2018; 32.
32. 32. Yang, W., et al., Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio are 2 new inflammatory markers associated with pulmonary involvement and disease activity in patients with dermatomyositis. Clin Chim Acta, 2017; 465: 11-6.
33. 33. Medsger, T.A., Jr., H. Robinson, and A.T. Masi, Factors affecting survivorship in polymyositis. A life-table study of 124 patients. Arthritis Rheum, 1971; 14: 249-58.
34. 34. Limaye, V., et al., Mortality and its predominant causes in a large cohort of patients with biopsy-determined inflammatory myositis. Intern Med J, 2012; 42: 191-8.
35. 35. Sunar, İ. and Ş. Ataman, Serum C-Reactive Protein/Albumin Ratio in Rheumatoid Arthritis and its Relationship With Disease Activity, Physical Function, and Quality of Life. 2020; 35: 247-53.
36. 36. Absenger, G., et al., A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer, 2013; 109: 395-400.
37. 37. Seringec Akkececi, N., et al., The C-Reactive Protein/Albumin Ratio and Complete Blood Count Parameters as Indicators of Disease Activity in Patients with Takayasu Arteritis. Med Sci Monit, 2019; 25: 1401- 09.
38. 38. Moon, J.S., et al., C-Reactive Protein to Serum Albumin Ratio Is an Independent Predictor of All-Cause Mortality in Patients with ANCA-Associated Vasculitis. 2018; 59: 865-71.